Patel Neeja, Karanth Rohan, Isaacs Dayna J, Cohen Joss, Wong Deborah J, Delshad Sean D
Internal Medicine, University of California Los Angeles Santa Monica Medical Center, Santa Monica, USA.
Neurology, University of California Los Angeles Santa Monica Medical Center, Santa Monica, USA.
Cureus. 2024 Oct 19;16(10):e71867. doi: 10.7759/cureus.71867. eCollection 2024 Oct.
Posterior reversible encephalopathy syndrome (PRES) is a neurologic condition with a constellation of symptoms, including altered mentation, headaches, and often seizures. Immunosuppressive therapies and, more recently, immunotherapy have been identified as risk factors for PRES. We describe the first documented case of PRES associated with a combination of pembrolizumab and cetuximab therapy. This case presentation aims to highlight a rare but potential adverse effect associated with immunotherapy. Awareness of this association and early recognition of symptoms can lead to prompt management and resolution of PRES. Further research is needed to elucidate the mechanisms and risk factors contributing to PRES.
后部可逆性脑病综合征（PRES）是一种具有一系列症状的神经系统疾病，包括精神状态改变、头痛，且常伴有癫痫发作。免疫抑制疗法以及最近的免疫疗法已被确定为PRES的危险因素。我们描述了首例有记录的与帕博利珠单抗和西妥昔单抗联合治疗相关的PRES病例。本病例报告旨在强调免疫疗法相关的一种罕见但潜在的不良反应。认识到这种关联并早期识别症状可促使对PRES进行及时处理和解决。需要进一步研究以阐明导致PRES的机制和危险因素。
